The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: US Stocks Seen Lower On Earnings, Ahead Of Data

Wed, 30th Apr 2014 12:04

LONDON (Alliance News) - US equities are set to open marginally lower Wednesday, as investors digest the latest tranche of quarterly trading statements released after the Wall Street close on Tuesday, and ahead of some important US macroeconomic data and the latest Federal Open Market Committee policy meeting decisions.

"US markets look set to open lower Wednesday as earnings from Twitter and eBay after the close yesterday pointed to lower-than-expected future growth," says Jasper Lawler, market analyst at CMC Markets.

Online retailer eBay posted a net loss of USD2.3 billion, or USD1.82 per share, in the first quarter, compared with net income of USD677 million in the same quarter last year. Although its quarterly earnings per share, excluding items, as well as quarterly revenue came in above analysts' expectations, the company's second-quarter guidance was weak.

Meanwhile, Twitter posted a net loss of USD132 million, or USD23 cents per share, in the first quarter, compared to a net loss of USD27 million in the same period last year. The company also issued 2014 revenue guidance that was lukewarm.

Twitter is down 13% in pre-market trading, while eBay is down 4.3%.

"Also playing into today's cautious approach from investors is likely to be the amount of important data releases lined up, not to mention the FOMC decision later on," says Craig Erlam, market analyst at Alpari.

"We've just come off two very good days, it is only logical to lock in some profits when there is GDP and ADP employment data and a central bank decision to come," he adds.

Ahead of the New York bell, the NASDAQ Composite is called to open down 0.3%, while the DJIA and S&P 500 are indicated to open marginally lower.

ADP employment change is released at 1215 GMT. Economists' expectations are for the reading, which is often regarded as indicative of the highly anticipated non-farm payrolls data released later in the week, to show that the private sector to have added 210,000 jobs compared to the 191,000 jobs added in March.

The preliminary reading of US first quarter GDP is published at 1230 GMT. This is "widely expected to be disappointing after the deep-freeze US winter," said Michael Hewson, chief market analyst at CMC Markets. An annualised reading of 1.2% is expected, down from 2.6% in the fourth quarter of last year.

The Chicago purchasing managers' index is released at 1345 GMT.

Later in the day, the US Federal Open Market Committee publishes its latest interest rate and monetary policy decisions at 1800 GMT.

In the UK, stocks continue to trade mixed. The FTSE 100 is up 0.2% at 6,786.08, the FTSE 250 is down 0.5% at 15,820.14, and the AIM All-Share index is up 0.8% at 822.28.

At the individual stock level, GlaxoSmithKline has just released its results for the first quarter of 2014. The drugs giant reported a drop in revenue and net profit for the quarter due to asset sales and a decline in sales of pharmaceuticals in the US, but the company also raised its dividend and reiterated its full-year profit guidance despite making its sales guidance more vague.

Its net profit fell to GBP668 million in the three months to end-March from GBP961 million a year earlier, as revenue declined to GBP5.61 billion from GBP6.47 billion. That was mainly due to asset sales and masked lower costs that resulted from its restructuring programme.

The company is is currently one of the biggest fallers in the blue-chip index, down 1.4%.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.